Cyfuse partners with Keio University and Fujita Health University for 3D bioprinted knee joint clinical trials

Cyfuse, a Tokyo-based bioprinting specialist, is entering a physician-led clinical trial starting in July 2024 in collaboration with Keio University and Fujita Health University. The clinical study focuses on the application of 3D bioprinted cell transplantation to achieve simultaneous repair of both knee bone and cartilage tissues. This partnership utilizes Cyfuse's proprietary bioprinting technology to deposit living cells into precise anatomical structures designed to facilitate regenerative healing in patients with joint degradation.

This development moves Cyfuse from the research and development phase into the highly regulated clinical validation stage of the biomanufacturing value chain. While traditional orthopedic implants rely on inert materials like Ti-6Al-4V or PEEK, this approach addresses the biological gap in tissue integration by using cell-laden bioinks. The success of this trial is critical for the bioprinting sector, which is currently transitioning from laboratory-scale prototyping to medical-grade production of complex, multi-material biological scaffolds. By targeting the knee joint, Cyfuse is addressing a high-demand orthopedic market segment where current regenerative medicine options remain limited.

For Cyfuse, the immediate priority is the successful execution of the clinical protocols and the management of regulatory data required for medical device and biological product approval in Japan. The company must demonstrate consistent print fidelity and cell viability across the bone-cartilage interface to prove the scalability of its bioprinting platform. This trial serves as the primary benchmark for whether their hardware can meet the rigorous standardization requirements of clinical-grade regenerative medicine.